Dublin-3 (Bpi-2358-103): A Global Phase (Ph) Iii Trial With The Plinabulin/Docetaxel (Plin/Doc) Combination Vs. Doc In 2nd/3rd Line Nsclc Patients (Pts) With Egfr-Wild Type (Wt) Progressing On A Prior Platinum-Based Regimen

PD1-i therapy is standard of care in 1st line, and Doc-based regimens in 2nd/3rd line EGFR-wt NSCLC pts. Doc improves survival, however, may negatively impact safety and quality of life (QoL). Plin, a novel immune-enhancing small molecule enhances dendritic cell maturation and T-Cell proliferation. Final survival, safety and QoL data of DUBLIN-3 are reported.